A recent study indicates that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise plans.
Findings released in a leading medical journal demonstrates that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Users buying such treatments must be cognizant of the potential of rapid weight regain when the treatment concludes," warns expert Dr. Susan Jebb.
Such speed of regain implies a return to starting mass in about 18 months.
Comparing Approaches
The research, which looked at dozens of trials involving thousands of patients, compared the results of GLP-1 agonists with conventional dieting.
Researchers note that people who lose weight through dieting usually have a less rapid creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Experts propose the mechanism of the drugs explains the amplified weight return.
These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone levels far above than the body's typical production could lead to the system to produce less of its own natural GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making excessive eating a significant risk."
A Chronic Disease?
The NHS recommend the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, due to the high risk of relapse, the therapy is often life-long.
This view is supported by pharmaceutical companies, who note that the results "underscore the long-term character of obesity," akin to managing diseases like high blood pressure.
User Experiences
People who have stopped the medication explain a intense resurgence of appetite.
"It felt as if a switch activating and you become ravenous," described one woman.
This challenge is exacerbated if patients have not established sustainable lifestyle or habit changes during treatment.
Growing Use
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Adoption is more common among women than males.
- The 40s and 50s age group shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, clinicians caution that while these medications are potent tools for shedding pounds, they are not a standalone fix and lasting health benefits hinges on ongoing behavioural support.
